TY - JOUR
T1 - Effects of add-on ultramicronized N-palmitol ethanol amide in patients suffering of migraine with aura
T2 - A pilot study
AU - Chirchiglia, Domenico
AU - Cione, Erika
AU - Caroleo, Maria C.
AU - Wang, Minyan
AU - Di Mizio, Giulio
AU - Faedda, Noemi
AU - Giacolini, Teodosio
AU - Siviglia, Serena
AU - Guidetti, Vincenzo
AU - Gallelli, Luca
N1 - Publisher Copyright:
© 2018 Chirchiglia, Cione, Caroleo, Wang, Di Mizio, Faedda, Giacolini, Siviglia, Guidetti and Gallelli.
PY - 2018/8/17
Y1 - 2018/8/17
N2 - Background: Palmitoyl ethanol amide (PEA) is an endogenously produced substance showing anti-nociceptive effect through both receptor and non-receptor mediated effects at the level of different cellular and tissue sites. This study showed the results of a single blind study that was conducted to evaluate both the safety and the efficacy of ultramicronized PEA (umPEA; 1,200 mg/day) for up 90 days in patients suffering of Migraine with Aura (MA) treated with NSAIDs. Methods: A total of 20 patients, 8 male (33-56-years, average 41.4 ± 7.8) and 12 female (19-61-years, average 38.5 ± 11.9) with MA were admitted to our observation and diagnosed according to ICHD-3 criteria, they received umPEA (1,200 mg/day) in combination with NSAIDs for up to 90 days. They were revaluated at 30, 60, and 90 days after treatment. Results: umPEA administration induced a statistically significant and time dependent pain relief. In particular, these effects were evident at 60 days (male P = 0.01189; female P = < 0.01) and they lasted until the end of the study (male P = 0.0066; female P = 0.01473). Conclusion: Although further studies are needed, our findings indicate that in patients suffering of MA treatment with umPEA had good efficacy and safety which candidate this compound as a therapeutic tool in pain migraine management.
AB - Background: Palmitoyl ethanol amide (PEA) is an endogenously produced substance showing anti-nociceptive effect through both receptor and non-receptor mediated effects at the level of different cellular and tissue sites. This study showed the results of a single blind study that was conducted to evaluate both the safety and the efficacy of ultramicronized PEA (umPEA; 1,200 mg/day) for up 90 days in patients suffering of Migraine with Aura (MA) treated with NSAIDs. Methods: A total of 20 patients, 8 male (33-56-years, average 41.4 ± 7.8) and 12 female (19-61-years, average 38.5 ± 11.9) with MA were admitted to our observation and diagnosed according to ICHD-3 criteria, they received umPEA (1,200 mg/day) in combination with NSAIDs for up to 90 days. They were revaluated at 30, 60, and 90 days after treatment. Results: umPEA administration induced a statistically significant and time dependent pain relief. In particular, these effects were evident at 60 days (male P = 0.01189; female P = < 0.01) and they lasted until the end of the study (male P = 0.0066; female P = 0.01473). Conclusion: Although further studies are needed, our findings indicate that in patients suffering of MA treatment with umPEA had good efficacy and safety which candidate this compound as a therapeutic tool in pain migraine management.
KW - Clinical trial
KW - Efficacy
KW - Migraine with aura
KW - Pain
KW - Safety
KW - Ultramicronized palmitoyl ethanol amide
UR - http://www.scopus.com/inward/record.url?scp=85052969796&partnerID=8YFLogxK
U2 - 10.3389/fneur.2018.00674
DO - 10.3389/fneur.2018.00674
M3 - Article
AN - SCOPUS:85052969796
SN - 1664-2295
VL - 9
JO - Frontiers in Neurology
JF - Frontiers in Neurology
IS - AUG
M1 - 674
ER -